tiprankstipranks
Trending News
More News >
Johnson & Johnson (JNJ)
:JNJ

Johnson & Johnson (JNJ) AI Stock Analysis

Compare
26,428 Followers

Top Page

JN

Johnson & Johnson

(NYSE:JNJ)

Rating:78Outperform
Price Target:
$175.00
▲(13.89%Upside)
Johnson & Johnson's overall stock score reflects its strong financial performance and earnings call highlights, which are the most significant factors. The company enjoys high profitability and effective cash flow management, with positive growth projections from strategic investments. Technical indicators are neutral, with no strong trend. Valuation is reasonable, supported by a healthy dividend yield. However, the impact of a recent bankruptcy plan rejection and challenges in some product lines pose risks.
Positive Factors
Oncology Advancements
Johnson & Johnson presented new data from its oncology portfolio, showcasing promising results in multiple myeloma treatments at a major cancer conference.
Product Momentum
Tremfya's rapid growth in the ulcerative colitis market is highlighted by strong commercial access and support, with potential to become a $10 billion+ product.
Strategic Acquisitions
Johnson & Johnson's acquisition of Intra-Cellular Therapies for USD 14.6 billion provides access to Caplyta and expands its portfolio in treating mental health disorders and neurological diseases.
Negative Factors
Biosimilar Competition
Amgen’s biosimilar Wezlana received FDA approval for interchangeability with Stelara, allowing pharmacists to substitute it freely, which may impact Stelara's sales.
Conflict of Interest
Investors should consider potential conflicts of interest that might affect the objectivity of certain analyst reports.
Price Pressure
Stelara is experiencing price pressure due to patent expiry and Medicare price negotiations, posing challenges to its market position.

Johnson & Johnson (JNJ) vs. SPDR S&P 500 ETF (SPY)

Johnson & Johnson Business Overview & Revenue Model

Company DescriptionJohnson & Johnson is a global leader in the healthcare industry, with operations spanning pharmaceuticals, medical devices, and consumer health products. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, and has a presence in over 60 countries. Its core products include prescription medicines, surgical equipment, diagnostic tools, and consumer health products such as baby care, skin care, and over-the-counter pharmaceuticals.
How the Company Makes MoneyJohnson & Johnson generates revenue primarily through its three business segments: Pharmaceutical, Medical Devices, and Consumer Health. The Pharmaceutical segment is the largest, focusing on areas such as immunology, oncology, neuroscience, and infectious diseases, delivering innovative treatments and therapies. The Medical Devices segment provides a wide range of products used in surgery, orthopedics, cardiovascular care, and diabetes care. The Consumer Health segment offers well-known brands like Neutrogena, Tylenol, and Johnson's Baby. The company also benefits from strategic partnerships, research and development investments, and a strong global distribution network, all contributing to its robust revenue streams.

Johnson & Johnson Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business units, highlighting which segments are driving growth and profitability, and indicating strategic focus areas.
Chart InsightsJohnson & Johnson's Pharmaceutical segment shows a robust recovery, driven by innovative medicines like DARZALEX and Tremfya, despite the STELARA sales decline. The MedTech segment is also experiencing steady growth, bolstered by strategic acquisitions. However, Consumer Health revenue has ceased, likely due to the segment's spin-off into Kenvue. The company's focus on innovation and strategic investments, as highlighted in the earnings call, positions it well for future growth, though challenges like tariff impacts and competitive pressures remain.
Data provided by:Main Street Data

Johnson & Johnson Earnings Call Summary

Earnings Call Date:Apr 15, 2025
(Q1-2025)
|
% Change Since: 0.40%|
Next Earnings Date:Jul 16, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong start to 2025 for Johnson & Johnson, driven by robust sales growth in innovative medicine and MedTech, significant oncology advancements, and strategic investments. However, challenges such as the decline in STELARA sales, tariff impacts, and orthopedics disruptions pose headwinds.
Q1-2025 Updates
Positive Updates
Strong Operational Sales Growth
Johnson & Johnson delivered a 4.2% operational sales growth in Q1 2025, with significant contributions from innovative medicine and MedTech sectors.
DARZALEX Performance
DARZALEX achieved over 20% growth, with sales above $3 billion for the third consecutive quarter, and expanded its indication in Europe for multiple myeloma.
Oncology Advancements
Riboflavin plus LASCRUZ showed over a year improvement in overall survival for EGFR-mutated lung cancer, and subcutaneous riboflavin was approved in Europe.
Tremfya's Market Impact
Tremfya entered the inflammatory bowel disease market, with a 20% sales growth, and is expected to become a $10 billion-plus product.
MedTech Segment Growth
MedTech delivered 4.1% operational sales growth, with strong performances in cardiovascular businesses and surgical vision.
Significant Investment Plans
Johnson & Johnson announced a $55 billion investment in the U.S. over the next four years, including four new manufacturing facilities.
Dividend Increase
The company increased its dividend for the sixty-third consecutive year.
Negative Updates
STELARA Sales Decline
STELARA sales faced a 32.3% decline due to biosimilar competition and Part D redesign.
Orthopedics Sales Impact
Orthopedics sales declined 3.1% due to one-time revenue recognition changes, fewer selling days, and transformation disruptions.
Gross Margin Pressure
Gross margins came in below trends due to STELARA's decline, currency headwinds, and Part D erosion.
Tariff Challenges
The company anticipates a $400 million impact from tariffs, affecting cost structures and pricing strategies.
Company Guidance
During the Johnson & Johnson First Quarter 2025 Earnings Conference Call, the company provided guidance and reported financial metrics reflecting strong operational sales growth of 4.2% across its business sectors. The innovative medicine segment saw a 4.2% sales increase despite an 810 basis points headwind from the loss of exclusivity on STELARA. Key brands, including DARZALEX, Tremfya, and Ribrofant plus LASCRUZ, showcased robust growth, with DARZALEX exceeding $3 billion in sales and Tremfya achieving 20% growth due to its new indications. The MedTech segment also reported a 4.1% sales increase, driven by strategic acquisitions such as Abiomed and Shockwave. The company raised its operational sales guidance for the full year to reflect the addition of Caplyta, projecting operational sales growth between 3.3% and 4.3%. This guidance incorporates a positive foreign currency impact, resulting in a full-year headwind of $600 million. Johnson & Johnson maintained its adjusted reported earnings per share guidance of $10.50 to $10.70, representing a 6.2% increase at the midpoint, despite challenges such as tariffs and biosimilar competition. The call underscored the company's commitment to innovation, highlighting plans for significant investments in R&D and manufacturing.

Johnson & Johnson Financial Statement Overview

Summary
Johnson & Johnson demonstrates solid financial performance with strong profitability margins and a stable balance sheet. The company exhibits low financial risk due to low leverage. However, slight declines in revenue growth and free cash flow highlight the need for strategic adjustments to sustain growth and cash generation.
Income Statement
85
Very Positive
Johnson & Johnson's income statement over the TTM (Trailing-Twelve-Months) shows robust financial health with a gross profit margin of 74.4% and a net profit margin of 26.6%, indicating strong profitability. The EBIT margin stands at 26.8%, and the EBITDA margin is 30.9%, both reflecting efficient operational management. However, the revenue growth rate from the previous year shows a slight decline of 7.7%, which is a potential concern for sustained growth.
Balance Sheet
80
Positive
The company's balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.18, suggesting low leverage and lower financial risk. The return on equity (ROE) is a healthy 27.9%, indicating effective use of equity. The equity ratio of 40.3% shows a strong capital structure. Despite these strengths, the decrease in stockholders' equity over the periods may need attention.
Cash Flow
78
Positive
The cash flow statement presents a stable cash generation with a free cash flow of $18.59 billion in the TTM and an operating cash flow to net income ratio of 1.14, indicating strong cash flow management. However, the drop in free cash flow growth by 6.3% compared to the previous year suggests potential challenges in maintaining cash flow levels.
Breakdown
TTMDec 2024Dec 2023Mar 2023Mar 2022Mar 2021
Income StatementTotal Revenue
89.33B88.82B85.16B79.99B78.74B82.58B
Gross Profit
61.01B61.35B58.61B55.39B55.34B54.16B
EBIT
22.07B22.15B23.41B21.01B20.94B19.73B
EBITDA
34.70B24.78B23.32B26.61B26.75B23.93B
Net Income Common Stockholders
21.81B14.07B35.15B17.94B20.88B14.71B
Balance SheetCash, Cash Equivalents and Short-Term Investments
38.78B24.52B22.93B22.28B31.61B25.18B
Total Assets
193.67B180.10B167.56B187.38B182.02B174.89B
Total Debt
52.25B36.63B29.33B39.64B33.75B35.27B
Net Debt
13.78B12.53B7.47B26.75B19.26B21.28B
Total Liabilities
115.56B108.61B98.78B110.57B108.00B111.62B
Stockholders Equity
78.11B71.49B68.77B76.80B74.02B63.28B
Cash FlowFree Cash Flow
18.57B19.84B18.25B17.18B19.76B20.19B
Operating Cash Flow
24.78B24.27B22.79B21.19B23.41B23.54B
Investing Cash Flow
-18.43B-18.60B878.00M-12.37B-8.68B-20.82B
Financing Cash Flow
6.74B-3.13B-15.82B-8.87B-14.05B-6.12B

Johnson & Johnson Technical Analysis

Technical Analysis Sentiment
Positive
Last Price153.66
Price Trends
50DMA
153.45
Positive
100DMA
154.48
Negative
200DMA
153.99
Negative
Market Momentum
MACD
0.20
Negative
RSI
51.72
Neutral
STOCH
54.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JNJ, the sentiment is Positive. The current price of 153.66 is above the 20-day moving average (MA) of 152.02, above the 50-day MA of 153.45, and below the 200-day MA of 153.99, indicating a neutral trend. The MACD of 0.20 indicates Negative momentum. The RSI at 51.72 is Neutral, neither overbought nor oversold. The STOCH value of 54.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JNJ.

Johnson & Johnson Risk Analysis

Johnson & Johnson disclosed 20 risk factors in its most recent earnings report. Johnson & Johnson reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Johnson & Johnson Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
JNJNJ
78
Outperform
$368.66B17.0829.45%3.28%-0.37%29.21%
AZAZN
77
Outperform
$223.47B28.6519.81%2.08%15.48%22.70%
MRMRK
76
Outperform
$193.70B11.2339.31%4.04%4.40%654.93%
75
Outperform
$155.70B26.43105.67%3.23%15.59%56.99%
PFPFE
72
Outperform
$132.75B16.928.62%7.27%13.38%
67
Neutral
$330.92B79.9488.15%3.40%5.45%-30.21%
54
Neutral
$5.28B3.29-45.38%2.80%16.77%-0.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JNJ
Johnson & Johnson
153.66
11.22
7.88%
AMGN
Amgen
287.10
-8.39
-2.84%
AZN
AstraZeneca
72.35
-6.09
-7.76%
MRK
Merck & Company
77.62
-49.29
-38.84%
PFE
Pfizer
23.12
-3.67
-13.70%
ABBV
AbbVie
187.47
23.99
14.67%

Johnson & Johnson Corporate Events

Executive/Board ChangesShareholder Meetings
Johnson & Johnson Shareholders Approve 2025 Director Nominees
Neutral
Apr 30, 2025

D. Adamczyk announced his intention to retire from Johnson & Johnson‘s Board of Directors effective May 31, 2025, to join Goldman Sachs as a Partner, citing personal reasons unrelated to any disagreements with the company. At the 2025 Annual Meeting of Shareholders held on April 24, 2025, all 11 Director nominees were elected, executive compensation policies were approved, and PricewaterhouseCoopers LLP was ratified as the independent auditor for 2025. However, proposals on shareholder voting for excessive golden parachutes and a human rights impact assessment were not approved.

Legal ProceedingsFinancial Disclosures
Johnson & Johnson Faces Bankruptcy Plan Rejection
Negative
Apr 3, 2025

On March 31, 2025, Johnson & Johnson announced that the U.S. Bankruptcy Court for the Southern District of Texas denied the request by its subsidiary, Red River Talc LLC, to confirm its proposed prepackaged bankruptcy plan. As a result, the company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution, impacting its financial planning and potentially affecting stakeholders’ expectations.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.